Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics.

Theophylline has been shown by several investigators to attenuate the late asthmatic response (LAR) to inhaled allergen, suggesting that it has anti-inflammatory or immunomodulatory properties. We have, therefore, undertaken a double-blind, placebo-controlled study to examine the effects of low-dose theophylline on bronchoalveolar lavage (BAL) and blood T-lymphocyte profile and activation in asthmatics following antigen challenge and the development of a LAR. Peripheral blood and BAL samples were obtained from 17 subjects with mild atopic asthma before and after 6 weeks of treatment with either oral theophylline or placebo. The mean serum theophylline concentration achieved was 6.6 micrograms.mL-1, which is below the currently accepted therapeutic range. Following theophylline therapy, there was a significant decrease in the number of BAL lymphocytes compared to placebo. On flow cytometric analysis of BAL cells, a significant loss of CD3+ T-lymphocytes, comprising both CD4+ and CD8+ subsets, was demonstrated. Moreover, there was a decrease in the number of BAL CD4+ T-cells expressing the activation marker very late activation antigen-1 (VLA-1), and an apparent reduction in human leucocyte antigen-DR (HLA-DR). Correspondingly, this was accompanied in the blood by an elevation in the proportion of activated CD4+ T-lymphocytes, in particular those expressing HLA-DR. These findings provide further evidence that theophylline has an anti-inflammatory action in asthma.

[1]  R. Dahl,et al.  Eosinophil and neutrophil activity in blood in asthma in a one-year-double-blind trail with Theophylline and two doses of inhaled Budesonide. The impact of smoking , 1995 .

[2]  C. Page,et al.  Anti-inflammatory effects of low-dose oral theophylline in atopic asthma , 1994, The Lancet.

[3]  M. Roth,et al.  Inhibition of natural killer cell activity by therapeutic levels of theophylline. , 1993, American journal of respiratory cell and molecular biology.

[4]  K P Jones,et al.  Guidelines on the management of asthma. , 1993, Thorax.

[5]  C. Page,et al.  Theophylline--an immunomodulatory role in asthma? , 1993, The American review of respiratory disease.

[6]  S. Holgate.  Mediator and cytokine mechanisms in asthma. , 1993, Thorax.

[7]  P. Howarth,et al.  Lymphocyte activation in bronchoalveolar lavage and peripheral blood in atopic asthma. , 1992, The American review of respiratory disease.

[8]  S. Durham,et al.  Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. , 1992, The New England journal of medicine.

[9]  C. Corrigan,et al.  T cells and eosinophils in the pathogenesis of asthma. , 1992, Immunology today.

[10]  J. Ribeiro,et al.  Theophylline therapy inhibits neutrophil and mononuclear cell chemotaxis from chronic asthmatic children. , 1991, British journal of clinical pharmacology.

[11]  B. Undem,et al.  Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. , 1991, Thorax.

[12]  A J Wardlaw,et al.  Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. , 1991, The Journal of clinical investigation.

[13]  M. Schuyler,et al.  Dynamic T-cell changes in peripheral blood and bronchoalveolar lavage after antigen bronchoprovocation in asthmatics. , 1991, The American review of respiratory disease.

[14]  L. Fabbri,et al.  Theophylline inhibits early and late asthmatic reactions induced by allergens in asthmatic subjects. , 1991, Annals of allergy.

[15]  S. Durham,et al.  Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. , 1990, The American review of respiratory disease.

[16]  J. Bousquet,et al.  Eosinophilic inflammation in asthma. , 1990, The New England journal of medicine.

[17]  Y. Mizushima,et al.  Inhibition of natural killer cell activity by oral administration of theophylline. , 1990, Chest.

[18]  S. Holgate,et al.  Cellular events in the bronchi in mild asthma and after bronchial provocation. , 1989, The American review of respiratory disease.

[19]  G. Canonica,et al.  Theophylline and the immune response: in vitro and in vivo effects. , 1988, Clinical immunology and immunopathology.

[20]  W. Owen,et al.  Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. , 1988, The Journal of clinical investigation.

[21]  C. Corrigan,et al.  T LYMPHOCYTE ACTIVATION IN ACUTE SEVERE ASTHMA , 1988, The Lancet.

[22]  J. Gamble,et al.  Recombinant human interleukin 5 is a selective activator of human eosinophil function , 1988, The Journal of experimental medicine.

[23]  S. Holgate,et al.  Recent advances in understanding the pathogenesis of asthma and its clinical implications. , 1988, The Quarterly journal of medicine.

[24]  A. Wardlaw,et al.  Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivity. , 1988, The American review of respiratory disease.

[25]  T. Casale,et al.  Direct evidence of a role for mast cells in the pathogenesis of antigen-induced bronchoconstriction. , 1987, The Journal of clinical investigation.

[26]  O. Cromwell,et al.  Allergen-induced recruitment of bronchoalveolar helper (OKT4) and suppressor (OKT8) T-cells in asthma. Relative increases in OKT8 cells in single early responders compared with those in late-phase responders. , 1987, The American review of respiratory disease.

[27]  P. O'Byrne,et al.  Late asthmatic responses. , 1987, The American review of respiratory disease.

[28]  P. O'Byrne,et al.  Bronchoalveolar cell profiles of asthmatic and nonasthmatic subjects. , 1987, The American review of respiratory disease.

[29]  G. Fink,et al.  Theophylline‐induced alterations in cellular immunity in asthmatic patients , 1987, Clinical allergy.

[30]  W. Owen,et al.  Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts , 1987, The Journal of experimental medicine.

[31]  R. Vestal,et al.  Therapeutic concentrations of theophylline and enprofylline potentiate catecholamine effects and inhibit leukocyte activation. , 1986, The Journal of allergy and clinical immunology.

[32]  C. Persson.  Overview of effects of theophylline. , 1986, The Journal of allergy and clinical immunology.

[33]  R. Pauwels,et al.  The effect of theophylline and enprofylline on allergen-induced bronchoconstriction. , 1985, The Journal of allergy and clinical immunology.

[34]  S. Durham,et al.  Eosinophils, bronchial hyperreactivity and late‐phase asthmatic reactions , 1985, Clinical allergy.

[35]  M. Topilsky,et al.  Effect of in vitro colchicine and oral theophylline on suppressor cell function of asthmatic patients. , 1985, Clinical and experimental immunology.

[36]  H. Sluiter,et al.  Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. , 1985, The American review of respiratory disease.

[37]  R. Pardi,et al.  In vivo effects of a single infusion of theophylline on human peripheral blood lymphocytes. , 1984, Clinical and experimental immunology.

[38]  A. Campbell,et al.  Changes in T-lymphocyte subpopulations after antigenic bronchial provocation in asthmatics. , 1984, The New England journal of medicine.

[39]  B. Volovitz,et al.  Induction of suppressor T cells in asthmatic children by theophylline treatment , 1983, Clinical allergy.

[40]  J. Pepys,et al.  Bronchial provocation tests in etiologic diagnosis and analysis of asthma. , 2015, The American review of respiratory disease.

[41]  H. Sluiter,et al.  Late bronchial obstructive reaction to experimental inhalation of house dust extract , 1972, Clinical allergy.